Antibodies to the Tyrosine Phosphatase-like Protein IA-2 are highly associated with IDDM, but not with Autoimmune Endocrine Diseases or Stiff Man Syndrome

References

• Bonifacio E., Bingley P. J., Shattock M., et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990; 335: 147–149
   PubMed Web of Science ®Google Scholar
• Riley W. J., Maclaren N. K., Krischer J., et al. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 1990; 323: 1167–1172
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Boitard C., Gleichmann H., Shattock M. A., Molenaar L. J., Bottazzo G. F. Assessment of precision, concordance, specificity and sensitivity of islet cell antibody measurement in 41 assays. Diabetolo-gia 1990; 33: 731–736
   PubMed Web of Science ®Google Scholar
• Greenbaum C. J., Palmer J. P., Nagataki S., et al. Improved specificity of ICA assays in the Fourth International Immunology of Diabetes serum exchange Workshop. Diabetes 1992; 41: 1570–1574
   PubMed Web of Science ®Google Scholar
• Roll U., Christie M. R., Standi E., Ziegler A. G. Associations of anti-GAD antibodies with islet cell antibodies and insulin autoantibodies in first-degree relatives of Type 1 diabetic patients. Diabetes 1994; 43: 154–160
   PubMed Web of Science ®Google Scholar
• Tuomilehto J., Zimmet P., Mackay I. R., et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994; 343: 1383–1385
   PubMed Web of Science ®Google Scholar
• Christie M., Tun R. Y. M., Lo S. S. S., et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies in identical twins. Diabetes 1992; 41: 782–787
   PubMed Web of Science ®Google Scholar
• Christie M., Tun R. Y. M., Lo S. S. S., et al. Detection of pancreatic islet 64,000 Mr autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J. Clin. Invest. 1993; 92: 240–248
   PubMed Web of Science ®Google Scholar
• Bingley P. J., Christie M. R., Bonifacio E., et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994; 43: 1304–1310
   PubMed Web of Science ®Google Scholar
• Christie M., Genovese S., Cassidy D., et al. Antibodies to islet 37 K antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994; 43: 1254–1259
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Genovese S., Braghi S., et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995; 38: 816–822
   PubMed Web of Science ®Google Scholar
• Payton M. A., Hawkes C. J., Christie M. R. Relationship of the 37,000-and 40,000Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J. Clin. Invest. 1995; 96: 1506–1511
   PubMed Web of Science ®Google Scholar
• Lan S. M., Lu J., Goto Y., Notkins A. L. Molecular Cloning and Identification of a Receptor-Type Protein Tyrosine Phosphatase, IA-2, from Human Insulinoma. DNA and Cell Biology 1994; 13: 505–514
   PubMed Web of Science ®Google Scholar
• Grubin C. E., Daniels T., Toivola B., et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344–350
   PubMed Web of Science ®Google Scholar
• Scherbaum W. A., Mirakian R., Pujol-Borrell R., Dean B. M., Bottazzo G. F. Immunochemistry in the study and diagnosis of organ-specific autoimmune disease. Immuncytochemistry. Modern Methods and Applications, J. M. Polak, S Van Noorden. Wright Bistrol, UK 1986; 456–476
   Google Scholar
• Petersen J. S., Hejnaes K. R., Moody A., et al. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994; 43: 459–467
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Lampasona V., Genovese S., et al. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40 k autoantigen and a target of islet-cell antibodies. J. Immunol 1995; 155: 5419–5426
   PubMed Web of Science ®Google Scholar
• Lu J., Li Q., Xie H., et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: Precursor of the 37-kDa tryptic fragment. Proc. Natl. Ac. Sci. 1996; 93: 2307–2311
   PubMed Web of Science ®Google Scholar
• Hawkes C. I., Wasmeier C., Christie M. R., Hut-Ton J. C. Identification of the 37 k-antigen in insulin-dependent diabetes as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996; 45: 1187–1192
   PubMed Web of Science ®Google Scholar
• Lan M. S., Wasserfall C, Maclaren N. K., Notkins A. L. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. 1996; 93: 6367–6370
   PubMed Web of Science ®Google Scholar
• Gianani R., Rabin D. U., Verge C. F., et al. ICA512 autoantibody radioassay. Diabetes 1995; 44: 1340–1344
   PubMed Web of Science ®Google Scholar
• Rabin D. U., Pleasic S. M., Shapiro J. A., et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunology 1994; 152: 3183–3188
   PubMed Web of Science ®Google Scholar
• Myers M. A., Rabin D. U., Rowley M. J. Pancreatic Islet cell antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 1995; 44: 1290–1295
   PubMed Web of Science ®Google Scholar
• Lampasona V., Bearzatto M., Genovese S., Bosi E., Ferrari M., Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the proein tyrosine phosphatase-like IA-2 autoantigen. J. Immunol. 1996; 157: 2707–2711
   PubMed Web of Science ®Google Scholar
• Hagopian W. A., Sanjeevi C. B., Kockum I., et al. Glutamate decarboxylase-, insulin-, and islet cell antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J. Clin. Invest. 1995; 95: 1505–1511
   PubMed Web of Science ®Google Scholar
• Seissler J., Amann J., Mauch L., et al. Prevalence of autoantibodies to the 65-and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993; 92: 1394–1399
   PubMed Web of Science ®Google Scholar
• Verge C. F., Howard N. J., Rowley M. J., et al. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia 1994; 37: 1113–1120
   PubMed Web of Science ®Google Scholar
• Verge C. F., Gianani R., Kawasaki E., Liping Y., Pietro-Paolo M., Jackson R. A., Chase H. P., Eisenbarth G. S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512 bdc/IA-2 autoantiodies. Diabetes 1996; 45: 926–933
   PubMed Web of Science ®Google Scholar
• Seissler J., Morgenthaler N. G., Achenbach P., et al. Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. Diabetologia 1996; 39: 1351–1356
   PubMed Web of Science ®Google Scholar
• Wagner R., Genovese S., Bosi E., et al. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 1994; bf37: 365–371
   Google Scholar
• Seissler J., Bieg S., Yassin N., et al. Association between antibodies to the Mr 67,000 isoform of Glutamate Decarboxylase (GAD) and Type 1 (insulin-dependent) diabetes mellitus with coexisting Autoimmune Polyendocrine Syndrome Type II. Autoimmunity 1994; 19: 231–238
   PubMed Web of Science ®Google Scholar
• Solimena M., Folli F., Aparisi R., Pozza G., De Camilli P. Autoantibodies to GABAergic neurons and pancreatic beta cells in stiff-man syndrome. N. Engl. J. Med. 1990; 322: 1555–1560
   PubMed Web of Science ®Google Scholar
• Meinck H. M., Ricker K., Hülser P. J., Schmid E., Peif-Fer J., Solimena M. Stiff man syndrome: clinical and laboratory findings in eight patients. J. Neurol 1994; 241: 157–166
   PubMed Web of Science ®Google Scholar
• Kim J., Namchuk M., Bugawan T., et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J. Exp. Med. 1994; 180: 595–606
   PubMed Web of Science ®Google Scholar
• Martino G., Grimaldi L. M. E., Bazzigaluppi E., Passim N., Sinigaglia F., Rogge L. The insulin-dependent diabetes mellitus-associated ICA 105 autoantigen in stiff-man syndrome patients. J. Neuroimmunol 1996; 69: 129–134
   PubMed Web of Science ®Google Scholar
• Folli F., Solimena M., Cofiell R., et al. Autoantibodies to a 128 kD synaptic protein in stiff-man syndrome with breast cancer. N. Engl. J. Med. 1993; 228: 564–551
   Google Scholar